FIELD: medicine.
SUBSTANCE: group of inventions concerns a composition for therapeutic delivery to tissue oxygen or carbon monoxide, containing a covalent conjugate functional natural haemoglobin molecule and at least one polyethylene glycol molecules, a water-soluble stabilizing component, a diluent. Group of inventions also concerns a method for preparing said composition; using said composition for preparing a drug for delivery of oxygen or carbon monoxide in tissue.
EFFECT: group of inventions provides oxygen delivery to tissues and improved stability of the composition during storage.
27 cl, 3 ex, 6 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IL-15 CONJUGATES AND THEIR USES | 2019 |
|
RU2793754C2 |
| INTERLEUKIN 10 CONJUGATES AND OPTIONS FOR THEIR USE | 2019 |
|
RU2815891C2 |
| METHOD OF PRODUCING POLYMER CONJUGATES | 2006 |
|
RU2401283C2 |
| PROTECTIVE COMPOSITIONS FOR ISCHEMIA/REPERFUSION AND METHODS FOR USING THEM | 2008 |
|
RU2459624C2 |
| CYTOKINE CONJUGATES FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2787201C2 |
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| METHODS FOR TREATING FIBROTIC CANCERS | 2014 |
|
RU2718056C2 |
| POLYPEPTIDES COMPRISING A SINGLE COVALENTLY BOUND N-TERMINAL WATER-SOLUBLE POLYMER | 1997 |
|
RU2199347C2 |
| COMPOSITIONS FOR T-CELL THERAPY WITH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2018 |
|
RU2819805C2 |
| HAPTOGLOBIN FOR USE IN TREATMENT OF UNFAVORABLE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING HAEMORRHAGIC STROKE | 2020 |
|
RU2818474C2 |
